News & Views | Published:

Clinical guidelines

Best practices and uncertainties in the management of PMR

Nature Reviews Rheumatology volume 12, pages 34 (2016) | Download Citation

Glucocorticoids are the mainstay of treatment for patients with polymyalgia rheumatica (PMR) and often produce substantial clinical improvements, but treatment can be complicated by relapse, adverse effects of therapies, and concomitant conditions. New recommendations aim to guide clinicians and improve the management of this disorder.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 74, 1799–1807 (2015).

  2. 2.

    et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 67, 2569–2580 (2015).

  3. 3.

    , , , & The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J. Rheumatol. 27, 2179–2184 (2000).

  4. 4.

    Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin. Arthritis Rheum. 33, 289–293 (2004).

  5. 5.

    , , & Diagnostic approach in a patient presenting with polymyalgia. Clin. Exp. Rheumatol. 17, 276–278 (1999).

  6. 6.

    , , & Polymyalgia rheumatica and giant-cell arteritis. N. Engl J. Med. 347, 261–271 (2002).

  7. 7.

    et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann. Rheum. Dis. 74, 1808–1817 (2015).

  8. 8.

    et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J. Rheumatol. 26, 1326–1332 (1999).

  9. 9.

    et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J. Rheumatol. 32, 65–73 (2005).

  10. 10.

    & Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin. Rheumatol. .

Download references

Acknowledgements

The work of M.A.G.-G. is supported by grants from Fondo de Investigaciones Sanitarias, Spain (PI06/0024, PS09/00748 and PI12/00060), and also partially supported by RETICS Program, RD08/0075 and RD12/0009/0013 (RIER) from Instituto de Salud Carlos III, Spain.

Author information

Affiliations

  1. Instituto de Investigación Sanitaria de Santiago, Division of Rheumatology, Santiago University Clinical Hospital, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain.

    • Miguel A. González-Gay
  2. University of Cantabria School of Medicine–IDIVAL-CIBERESP, Avenida Herrera Oria s/n, 39011 Santander, Spain.

    • Javier Llorca

Authors

  1. Search for Miguel A. González-Gay in:

  2. Search for Javier Llorca in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Miguel A. González-Gay.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrrheum.2015.142

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing